Draft Amendment no. 2

Notice Inviting Tender Ref No.: - BPPI/DRUG/RC-156/2020 **Dated: 30/07/2020**

Subject: - Tender No. BPPI/DRUG/RC-156/2020 dated 17/07/2020 for supply of drug/medicine to Bureau of Pharma Public Sector undertakings of India (BPPI).

Reference: - Pre-Bid meeting held on 24/07/2020 at 11:00 AM in the premises of BPPI.

Bureau of Pharma PSUs of India (BPPI) has invited e-Bids from the interested parties for "e- Tender For Supply of Drug/Medicine for the year 2020- 2022", vide Notice Inviting Tender No.- **BPPI/DRUG/RC-156/2020**. Detailed tender document containing eligibility criteria, selection mechanism, other terms and conditions are available on the website of Central Public Procurement Portal; www.eprocure.gov.in and BPPI Website; www.janaushadhi.gov.in .

After considering the suggestions/ queries received from the prospective bidders on or before Pre-Bid meeting, the clarifications/ amendments with regard to the tender document and quantity of the tendered items have been made as per Annexure-A and Annexure-B respectively. All other technical specifications, terms and conditions along with the tender schedule as mentioned in tender document shall remain unchanged.

The following amendment in Tender Document is hereby authorized: -

Annexure- A

Sl. No.	Tender Clause/Reference	Query/Suggestion	Clarification/ Amendment
1	**Clause no. 3. E.** ELIGIBILITY CRITERIA (TECHNICAL BID -COVER "A"):	One of the bidders in the Pre-bid meeting has raised their query saying State Licencing Authority issues Market Standing Certificate without mentioning Batch no. of quoted items in the certificate.	It was clarified to bidders that the certificate must certify that the bidder has manufactured at least two batches in last three years. The certificate shall be issued as per the format of State Licencing Authority.
2	**Clause no. 3. E.** ELIGIBILITY CRITERIA (TECHNICAL BID -COVER "A"):	Few of the bidders in the Pre-bid meeting has requested to relax **Market Standing Certificate in case of DC 1461, 1462, 1463 and 1837.** They have stated that the drug Vildagliptin was under patent till **December 2019.** They have also requested to relax **Market Standing Certificate** for **Hand sanitizer** saying this product has come in trend due to **"COVID 19"** and to allow healthy competition bidders have requested to relax **Market Standing Certificate**	The following Clause is here by added as 'Note' in continuation to **Clause no. 3. E (**ELIGIBILITY CRITERIA (TECHNICAL BID -COVER "A"). Note: Market Standing Certificate for DC 1461,1462, 1463, 1837, 1473, 1474 and 1475 are relaxed from participating in the tender.

3	ANNEXURE-XIV Ref. Clause No. 1(ii) C	Bidder has requested to amend Column "Shape and Size of Tablets/ Capsule / unit pack type" in ANNEXURE- XIV for most of the drugs in Pre-bid meeting as well as vide their mail.	The column indicating "Size of Tablets/ Capsule / unit pack type" in ANNEXURE- XIV is hereby deleted from the tender document. Bidders must supply the drugs as per market standard.
4	ANNEXURE-XIV Ref. Clause No. 1(ii) C	Bidder has requested to amend "PVC Colour / bottle shape" column in ANNEXURE- XIV for most of the drugs in Pre-bid meeting as well as vide their mail.	The column indicating "PVC Colour / bottle shape" in ANNEXURE- XIV is hereby deleted from the tender document. Bidders must supply the drugs as per market standard. The following Clause is here by added as 'Note' in continuation to ANNEXURE- XIV: Note: (i) Drugs (Tablet/Capsule) supplied in strips/ Alu-Alu pack shall be in silver colour. (ii) Drugs (Tablet/Capsule) supplied in Blister pack shall be in transparent colour PVC except for light sensitive drugs which must be supplied in amber colour PVC.
5		One of the bidders has requested to clarify if the tendered drug is in PR (Prolonged Release), they have also requested to accept the drug licence with SR (Sustained Release)/ ER (Extended Release) form.	Drugs Licence may be accepted in either of the SR (Sustained Release)/ PR(Prolonged Release)/ ER (Extended Release) form if the tendered drug is asked in any of the above form.

Annexure- B: -

Part- A

Sl. No.	Tender Clause/ Reference	Drug Code with Generic Name of the Drug	Composition of the Drug in tender	Amendment
1	Annexure - XII Clause 18 (M) & BOQ	DC 115 Calamine Lotion	Composition: Calamine 15% w/v Zinc Oxide 5% w/v Bentonite 3% w/v Sodium Citrate 0.5% w/v Glycerol 5% v/v	The following Amendment is hereby authorized as below: - Composition: Calamine 150 g Zinc Oxide 50 g Bentonite 30 g Sodium Citrate 5 g Glycerine 50 ml Liquified Phenol 5 ml
2	Annexure -XII Clause 18 (M) & BOQ	DC 252, Montelukast Sodium and Levocetirizine Tablets IP (10mg + 5mg)	Each film coated tablet contains: Montelukast Sodium IP equivalent to Montelukast: 10 mg Levocetirizine Dihydrochloride :5 mg Excipients: q.s	The following Amendment is hereby authorized as below: - Each film coated tablet contains: Montelukast Sodium IP equivalent to Montelukast: 10 mg Levocetirizine hydrochloride: 5 mg

3	Annexure -XII Clause 18 (M) & BOQ	DC 312, Oral Rehydration Salts 20.5 g Sachet (WHO Formula)	Each pack contains: Sodium Chloride IP 2.6 mg Potassium Chloride IP 1.5 mg Sodium Citrate IP 2.9 mg Dextrose IP (anhydrous) 13.5 mg Excipients q.s.	The following Amendment is hereby authorized as below: - Each Sachet of 20.5g contains: Sodium Chloride IP 2.6 g Potassium Chloride IP 1.5 g Sodium Citrate IP 2.9 g Dextrose IP (anhydrous) 13.5 g Excipients q.s.
4	Annexure -XII Clause 18 (M) & BOQ	DC 467, Dicyclomine and Mefenamic Acid Tablets (10mg + 250mg)	Each Uncoated Sublingual Tablets contains: Mefenamic Acid IP 250mg Dicyclomine Hydrochloride IP 10 mg	The following Amendment is hereby authorized as below: - Each Uncoated tablet contains: Mefenamic Acid IP 250mg Dicyclomine Hydrochloride IP 10 mg
5	Annexure -XII Clause 18 (M) & BOQ	DC 499, Norethisterone Tablets IP 5 mg	Each Uncoated Sublingual Tablets contains: Norethisterone IP 5mg	The following Amendment is hereby authorized as below: - Each Uncoated Tablets contains: Norethisterone IP 5mg
6	Annexure -XII Clause 18 (M) & BOQ	DC 556, Montelukast and Fexofenadine Hydrochloride Tablets (10mg + 120mg)	Each Film Coated Tablets Contains: Fexofenadine Hydrochloride IP 500 mg Montelukast Sodium IP equivalent to Montelukast 10mg	The following Amendment is hereby authorized as below: - Each Film Coated Tablets Contains: Montelukast Sodium IP equivalent to Montelukast 10mg Fexofenadine Hydrochloride IP 120 mg
7	Annexure -XII Clause 18 (M) & BOQ	DC 568, Salmeterol and Fluticasone Propionate Inhaler IP (25mcg+250mcg)	Each activation delivers: Salmeterol (as Salmeterol Xinofoate) 50mcg Fluticasone Propionate 250mcg	The following Amendment is hereby authorized as Xinofoate: - Each activation delivers: Salmeterol (as Salmeterol Xinofoate) 25mcg Fluticasone Propionate 250mcg
8	Annexure -XII Clause 18 (M) & BOQ	DC 665, Vitamin B Complex and Ascorbic Acid Capsules	Each hard gelatin capsule contains: Thiamine 10mg Riboflavin 10mg Niacinamide 50mg 9Pyridoxine Hydrochloride 3mg Cynocobalamine 50mcg Calcium Pantothenate 12.5mg Folic acid 1mg Ascorbic acid 150mg	The following Amendment is hereby authorized as follow: - Each soft gelatin capsule contains: Thiamine (Vit. B1) 10mg Riboflavin (Vit. B2) 10mg Niacinamide (Vit. B3) 50mg Pyridoxine Hydrochloride (Vit. B6) 3mg Cynocobalamine (Vit. B12) 5mcg Calcium Pantothenate 12.5mg Folic acid 1mg Ascorbic acid (Vitamin C) 150mg

9	Annexure -XII Clause 18 (M) & BOQ	DC 781, Alprazolam and Fluoxetine Tablets (0.25mg+20mg)	Each Film Coated tablet contains: Fluoxetine Hydrochloride IP eq. to Fluoxetine 20mg Alprazolam IP 0.25 mg	The following Amendment is hereby authorized as follow: - Each Uncoated tablet contains: Fluoxetine Hydrochloride IP eq. to Fluoxetine 20mg Alprazolam IP 0.25 mg
10	Annexure -XII Clause 18 (M) & BOQ	DC 1097, Vitamin A Capsule 25000 IU	Each soft gelatin capsule contains: Vitamin A IP (as Palmitate) 25000 IU (equivalent to Retinol 7.5 mg) in water soluble form.	The following Amendment is hereby authorized in the Generic name and composition of the drug: - **Vitamin A Capsule IP 25000 IU** Each soft gelatin capsule contains: Vitamin A (as concentrate oil) IP 25000 IU
11	Annexure -XII Clause 18 (M) & BOQ	DC 1493, Aceclofenac, Paracetamol & Thiocolchicoside Tablets (4/100/500mg)	Each Film coated tablets contains: Thiocolchicoside 4mg Aceclofenac 100mg Paracetamol 500mg	The following Amendment is hereby authorized in the Generic name and composition of the drug: - **Aceclofenac, Paracetamol & Thiocolchicoside Tablets (100/325/4mg)** Each Film coated tablets contains: Aceclofenac 100 mg Paracetamol 325 mg Thiocolchicoside 4 mg
12	Annexure -XII Clause 18 (M) & BOQ	DC 1640, Gabapentin 300 mg and Methylcobalamin 500 mg Tablet	Each film-coated tablet contains: Gabapentin 300 mg Methylcobalamin 500 mg	The following Amendment is hereby authorized in the Generic name and composition of the drug: - **Gabapentin and Methylcobalamin Tablets (300mg + 500mcg)** Each film-coated tablet contains: Gabapentin 300 mg Methylcobalamin 500 mcg
14	Annexure -XII Clause 18 (M) & BOQ	DC 1670, Isotretinoin 20 mg Capsule	Each soft-Gelatin capsule contains: Isotretinoin 20 mg	The following amendment is authorised in the unit size and pack size: **Unit Size:** 10's in mono-carton **Pack Size:** 10's in mono-carton X 10
15	Annexure -XII Clause 18 (M) & BOQ	DC 1693, Levosulpiride SR 75 mg and Rabeprazole EC 20 mg Capsule	Each soft-Gelatin capsule contains: Levosulpiride 75 mg (Sustained Release) Rabeprazole 20 mg (Enteric coated	The following Amendment is hereby authorized as follow: - Each Hard Gelatin capsule contains: Levosulpiride 75 mg (Sustained Release) Rabeprazole Sodium 20 mg (Enteric coated
16	Annexure -XII Clause 18 (M) & BOQ	DC 1724, Nimesulide 100 mg and Paracetamol 500 mg Tablet	Each uncoated tablet contains: Nimesulide 100 mg Paracetamol 500 mg	The following Amendment is hereby authorized in the Generic name and composition of the drug: - **Nimesulide and Paracetamol Tablets (100mg+325mg)** Each uncoated tablet contains: Nimesulide 100 mg Paracetamol 325 mg

17	Annexure -XII Clause 18 (M) & BOQ	DC 1765, Pregabalin 75 mg and Methylcobalamin 750 m Capsule	Each Hard Gelatin capsule contains: Pregabalin 75 mg Methylcobalamin 750 mcg	The following Amendment is hereby authorized in the Generic name and composition of the drug: - **Pregabalin and Methylcobalamin Capsules IP (75mg + 750mcg)** Each Hard Gelatine capsule contains: Pregabalin IP 75 mg Methylcobalamin IP 750 mcg
18	Annexure -XII Clause 18 (M) & BOQ	DC 1809, Sucralfate Suspension 1gm/5ml	Each 5ml contains: Sucralfate 1g	The following amendment is hereby authorised in the unit size: **Unit Size: 200ml**

Part-B

Sl. No.	Tender Clause/ Reference	Drug Code with Generic Name of the Drug	Amendment in Packaging Type
1	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-126 Povidone-Iodine Solution IP 10 % w/v	The following amendment is hereby authorised in the **Packaging** type: Plastic Bottle
2	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-132 Silver Sulfadiazine Cream IP 1% w/w 500g	The following amendment is hereby authorised in the **Packaging** type: HDPE Jar
3	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-195 Isapgol Husk IP 200 gm	The following amendment is hereby authorised in the **Packaging** type: Tetra pack
4	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-227 Polyvitamin Tablets NFI (Prophylactic)	The following amendment is hereby authorised in the **Packaging** type: Blister
5	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-251 Montelukast Sodium Tablets IP 10mg	The following amendment is hereby authorised in the **Packaging** type: ALU-ALU
6	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-266 Atorvastatin Tablets IP 10mg	The following amendment is hereby authorised in the **Packaging** type: ALU-ALU
7	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-275 Enalapril Tablets IP 5 mg	The following amendment is hereby authorised in the **Packaging** type: Strip
8	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-494 ISPAGHULA HUSK IP 100 GM	The following amendment is hereby authorised in the **Packaging** type: Tetra-pack
9	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-644 Phenylephrine Hydrochloride 5.00mg Chlorpheniramine Maleate 2.00mg Drops	The following amendment is hereby authorised in the **Packaging** type: Plastic Bottle
10	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-779 Alpha Lipoic acid 100mg Vit. D3 1000 IU Folic acid 1.5mg Pyridoxine 3mg Methylcobalamin 1500mcg	The following amendment is hereby authorised in the **Packaging** type: Strip
11	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1060 Sodium Valproate Gastro-Resistant Tablets IP 300mg	The following amendment is hereby authorised in the **Packaging** type: Strip

12	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1383 Pregabalin and Nortriptyline Tablets (75mg+10 mg)	The following amendment is hereby authorised in the **Packaging** type: ALU-ALU
13	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1410 Telmisartan, Amlodipine and Hydrochlorothiazide Tablets (40mg+5mg+12.5mg)	The following amendment is hereby authorised in the **Packaging** type: ALU-ALU
14	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1520 Azilsartan Medoxomil Tablets 40mg	The following amendment is hereby authorised in the **Packaging** type: ALU-ALU
15	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1525 Betahistine Tablets IP 16 mg	The following amendment is hereby authorised in the **Packaging** type: Strip
16	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1526 Betahistine Tablets IP 24 mg	The following amendment is hereby authorised in the **Packaging** type: Strip
17	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1548 Cefixime Oral Suspension IP 100 mg/ 5ml	The following amendment is hereby authorised in the **Packaging** type: HDPE Bottle
18	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1550 Cefixime Oral Suspension IP 50 mg/ 5ml	The following amendment is hereby authorised in the **Packaging** type: HDPE Bottle
19	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1553 Cefpodoxime Oral Suspension IP 100mg	The following amendment is hereby authorised in the **Packaging** type: HDPE Bottle
20	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1571 Clidinium Bromide, Chlordiazepoxide and Dicyclomine Hydrochloride Tablets (2.5mg / 5mg / 10mg)	The following amendment is hereby authorised in the **Packaging** type: Blister
21	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1583 Clotrimazole Mouth Paint (1% w/v)	The following amendment is hereby authorised in the **Packaging** type: Plastic Bottle
22	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1608 Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets IP (600mg / 200mg / 300mg)	The following amendment is hereby authorised in the **Packaging** type: Bottle
23	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1611 Emtricitabine and Tenofovir Disoproxil Fumarate Tablets IP (200mg / 300mg)	The following amendment is hereby authorised in the **Packaging** type: Bottle
24	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1748 Paracetamol 250 mg, Caffeine 50 mg and Phenazone 150 mg Tablet	The following amendment is hereby authorised in the **Packaging** type: Blister
25	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1809 Sucralfate Suspension 1gm/5ml	The following amendment is hereby authorised in the **Packaging** type: HDPE Bottle
26	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1811 Telmisartan and Amlodipine Tablets IP (80/5mg)	The following amendment is hereby authorised in the **Packaging** type: Strip
27	ANNEXURE- XIV Ref. Clause No. 1(ii) C & Para (II) C of Annexure II	DC-1813 Telmisartan Tablets IP 80mg	The following amendment is hereby authorised in the **Packaging** type: Strip

Part-C

The following drugs/medicines is hereby deleted from the Annexure- XII, Annexure XIV of the tender document and BOQ. Details are as below: -

Sl. No.	Drug Code	Generic name of the drug	Unit Size
1	1546	**Cefixime and Azithromycin Tablets (200mg / 250mg)** Each film coated tablet contains: Cefixime IP (as Trihydrate) equivalent to Anhydrous Cefixime 200 mg Azithromycin IP (as dihydrate) equivalent to Anhydrous Azithromycin 250 mg	10's
2	1547	**Cefixime and Ornidazole Tablets (200mg / 500mg)** Each film coated tablet contains: Cefixime IP (as Trihydrate) equivalent to Anhydrous Cefixime 200 mg Ornidazole 500 mg	10's
3	1641	**Gabapentin 300 mg Capsule** Each capsule contains: Gabapentin 300 mg	15's
4	1702	**Meropenem Injection 500mg** Each Vial Contains: Meropenem (sterile) equivalent to Meropenem 500mg	Vial with WFI

All other contents of tender document remain unaltered. Bidders are requested to quote their rates considering all the terms and condition of the tender document including Amendment no. 1 & Amendment no. 2 dated 30/07/2020.

Sd/-
Manager (Procurement)
For & on behalf of BPPI
PH: 011-49431812